These findings suggested that apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in a zebrafish model of NSCLC, which involves the synergistic inhibition of the VEGFR2, EFNB2A, ROBO4, and FGFR4 signaling pathways. Here, KDR is linked to non-small cell lung carcinoma.